Pretransplantation Cognitive Dysfunction in Advanced-Age Hematologic Cancers: Predictors and Associated Outcomes

Root, James C.; Campbell, Claudine; Rocha-Cadman, Xiomara; Kasven-Gonzalez, Nicole; Maloy, Molly; Flynn, Jessica; Devlin, Sean M.; Jakubowski, Ann A.

doi:10.1016/j.bbmt.2020.05.010

Cited by 8 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Greater awareness has emerged that age alone is not the sole defining factor for eligibility 8,9 . Instead, it is an additional aspect that must be considered together with comorbidities 7 and cognition 10 . This shift has changed the life stories of many previously ineligible patients.…”

Section: Discussionmentioning

confidence: 99%

The role of a Hematology outpatient clinic in improving access to bone marrow transplantation in low-middle-income countries.

Barroso Duarte,

Garcia,

Cristiny Remigio Pitombeira

et al. 2024

jbmtct

View full text Add to dashboard Cite

Discutir a elegibilidade precocemente no Transplante de Medula Óssea (TMO) reduz o tempo de espera, a busca de doadores e acelera o acesso aos cuidados pré-transplante. O estudo descreve a otimização do acesso ao TMO por meio de um ambulatório para avaliação de pacientes pré-transplante. Estudo retrospectivo, 2021-2023 no Hospital Universitário Walter Cantídio. Dados analisados no SPSS. Mostra 226 transplantes de 3.646 consultas. A clínica encaminhou 45 pacientes, contribuindo com 19,1%, 11,7% e 22,1% dos transplantes em 2021, 2022 e 2023, respectivamente, em comparação com <5% nos anos anteriores. Este aumento destaca a importância do acesso rápido aos cuidados pré-transplante, resultando num maior número de pacientes elegíveis para transplante.

show abstract

Section: Discussionmentioning

confidence: 99%

The role of a Hematology outpatient clinic in improving access to bone marrow transplantation in low-middle-income countries.

Barroso Duarte,

Garcia,

Cristiny Remigio Pitombeira

et al. 2024

jbmtct

View full text Add to dashboard Cite

show abstract

“…Z kolei Root i wsp. wskazują na wyniki poniżej 26 pkt wśród pacjentów poddanych chemioterapiom z powodu nowotworów krwi [19]. Podobną obserwację czynią Wang i wsp.…”

Section: Montrealska Ocena Poznawczaunclassified

Diagnosis of chemotherapy-related cognitive impairment

Dunaj¹,

Piechowicz²,

Kołodziejczyk³

et al. 2022

View full text Add to dashboard Cite

Zaburzenia poznawcze mogą być skutkiem chemioterapii stosowanej wśród pacjentów onkologicznych. Ta dolegliwość, inaczej zwana chemobrain, obniża jakość codziennego życia wydłużonego dzięki chemioterapeutykom. Wydaje się za to odpowiadać neurotoksyczność stosowanych leków, skutkująca zaburzeniem struktury i funkcji tkanki nerwowej ośrodkowego układu nerwowego. Powstałe zmiany patologiczne są możliwe do wykrycia podczas właściwie przeprowadzonego procesu diagnostycznego. Obecnie nie istnieją konkretne wytyczne diagnostyki chemobrain, jednak obiecujące wydaje się wykorzystanie metod z zakresu psychologii, diagnostyki laboratoryjnej i obrazowej. Badania psychologiczne za pomocą wystandaryzowanych kwestionariuszy pozwalają obiektywnie ocenić objawy dysfunkcji poznawczych zgłaszane przez pacjenta. Analiza laboratoryjna płynów ustrojowych umożliwia wykrycie charakterystycznych biomarkerów, natomiast obrazowanie struktur ośrodkowego układu nerwowego pozwala wskazać patologiczne zmiany w regionach mózgu, skutkujące powstaniem opisywanych zaburzeń. Kluczową rolę w postawieniu właściwego rozpoznania klinicznego odgrywa badanie podmiotowe i przedmiotowe pacjenta onkologicznego po przebytej chemioterapii. Im wcześniej zostanie stwierdzone zaburzenie funkcji poznawczych, tym większa szansa osiągnięcia sukcesu terapeutycznego z zastosowaniem obecnie proponowanych metod leczniczych. W niniejszej publikacji przedstawiono przegląd dostępnej literatury na temat stosowanych metod diagnostyki chemobrain.

show abstract

“…Neurocognitive dysfunction has been documented in multiple myeloma (MM) patients after HDC and preautologous SCT (ASCT) with declines post-HDC/ASCT (Jones, Vichaya et al 2013, Root, Campbell et al 2020; however, other studies reported improvement in neurocognitive function (NF) months postchemotherapy (Jacobs, Small et al 2007, Bury-Kaminska, Szudy-Szczyrek et al 2021). Pro-in ammatory cytokines (PCy) play a critical role in tumor growth and progression in MM, with high levels identi ed in many patients (Musolino, Allegra et al 2017).…”

Section: Introductionmentioning

confidence: 99%

Neuroimaging and Neurocognitive Outcomes in Older Patients with Multiple Myeloma Treated with Chemotherapy and Autologous Stem Cell Transplantation

Correa

Vachha

Baser

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background Many patients with hematological malignancies treated with stem cell transplantation (SCT) experience cognitive dysfunction. However, few studies have investigated treatment-related neurotoxicity in older adults with multiple myeloma (MM) treated with high dose chemotherapy (HDC) and autologous SCT (HDC/ASCT). In this study, we examined gray matter (GM) volume, resting state functional connectivity (RSFC), neurocognitive function (NF), and proinflammatory cytokines (PCy) in older patients with MM pre- and post-HDC/ASCT. Methods Eighteen MM patients underwent magnetic resonance imaging, neurocognitive tests, and serum PCy measurement prior to HDC/ASCT, and fifteen patients completed follow ups an average of five months post-HDC/ASCT. Results There were significant decreases in RSFC from pre- to post-HDC/ASCT in (1) the central executive network (CEN) involving the left dorsolateral prefrontal cortex and right posterior parietal cortex (p = 0.022), and (2) the CEN involving the right posterior parietal cortex and the salience network involving the right dorsal anterior cingulate cortex (p = 0.029); these comparisons were no longer significant after multiple comparisons correction. There were no significant changes in GM volumes or NF, except for improvement in attention (Digit Span Backward, p = 0.03). There were significant increases in several PCy post-HDC/ASCT (p ≤ 0.05). Conclusions This pilot study showed decreased RSFC involving the left frontal, right posterior parietal and right anterior cingulate cortices in MM patients post-HDC/ASCT, relatively stable NF, and increases in PCy. These findings are congruent with studies in patients with hematological malignancies and other cancers and provide supporting evidence for the vulnerability of frontoparietal regions to chemotherapy adverse effects.

show abstract

Pretransplantation Cognitive Dysfunction in Advanced-Age Hematologic Cancers: Predictors and Associated Outcomes

Cited by 8 publications

References 26 publications

The role of a Hematology outpatient clinic in improving access to bone marrow transplantation in low-middle-income countries.

The role of a Hematology outpatient clinic in improving access to bone marrow transplantation in low-middle-income countries.

Diagnosis of chemotherapy-related cognitive impairment

Neuroimaging and Neurocognitive Outcomes in Older Patients with Multiple Myeloma Treated with Chemotherapy and Autologous Stem Cell Transplantation

Contact Info

Product

Resources

About